Control leukemia

by inducing
anti-cancer vaccines
in vivo

Immunotherapy
made easy

Specific anti-cancer vaccines in vivo.

Modiblast targets the core issue in acute myeloid leukemia (AML), the extremely high rate of relapses after successful initial therapy. We repurpose approved drugs that induce blast cells in the patient to differentiate into leukemia-specific dendritic cells (DCleu) that can trigger both innate and adaptive immunity in blood/tissue to kill remaining/recurring blasts and generate memory cells.

Vision Mission

Creating therapeutic options for acute myeloid leukemia and high risk myelodysplastic syndrome

Blood cancer facts

Acute myeloid leukemia (AML):
grasping this fast progressing blood cancer in numbers.

Management
Team

Experience joins passion:
get to know the individuals who drive Modiblast forward

History

The scientific foundations of Modiblast were laid almost twenty years before the company was established in early 2020. When Helga Schmetzer started to work in immunology and cancer diagnostics, she quickly became aware of the fundamental role of dendritic cells in fighting off leukemic cells (so-called blasts).

Using immunological, molecular, and chromosomal methods to detect and characterize (residual) disease in patients with leukemia, she realized that …

CONTROL LEUKEMIA

We use approved drugs to induce personalized anti-leukemia "vaccines" in vivo.

„The Modiblast approach may entail substantial advantages compared to other therapies in the state-of-the-art“

Prof. Dr. Dr. Ulrike Köhl

Director Fraunhofer Institute for Cell Therapy and Immunobiology, Leipzig

modiblast-logo-weiß.jpg

General Managers:
Prof. Dr. Helga Schmetzer,
Dr. Octavian Schatz,
Dr. Nikolaus Schaller

Registration: HRB 254854,
Amtsgericht München
VAT-ID: DE328961565

LEGAL

Terms
Imprint
Data protection

SERVICE

About
Technology
News

CONTACT

Modiblast Pharma GmbH
Buchenstraße 3
82041 Oberhaching
Germany
Tel. +49-89-1226-4666
contact@modiblast.com

© Copyright Modiblast 2022. All Rights Reserved.